Alector vs 4D Molecular Therapeutics
ALEC and FDMT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALEC and FDMT compare
4D Molecular Therapeutics is the larger company, worth 3.2 times as much as Alector ($938M against $294M).
4D Molecular Therapeutics grew revenue faster over the last twelve months (278712% versus 151% for Alector).
Alector keeps more of each dollar of sales as profit, with a net margin of 23.9% compared with −195% at 4D Molecular Therapeutics.
Alector scores higher on the StockData Score (12 against 7 for 4D Molecular Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALEC | FDMT |
|---|---|---|
| Size and price | ||
| Market cap | $294M | $938M |
| Share price | $2.63 | $12.99 |
| Change, 1 year | 101% | 27.7% |
| Change, 5 years | −87.7% | −43.7% |
| Beta (5Y) | 1.51 | 1.35 |
| Employees | 103 | 196 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 7.5× | – |
| P/S | 1.7× (better) | 10.2× |
| P/B | 2.5× | 2.3× (better) |
| EV/EBITDA | 3.9× | – |
| FCF yield | −51.1% | – |
| Fair value | $8.06 | $12.76 |
| Margin of safety | 67.4% (better) | −1.8% |
| Growth | ||
| Revenue growth (TTM) | 151% | 278712% (better) |
| Revenue growth, 5Y average | −0.05% | 44.3% (better) |
| Profitability | ||
| Operating margin | 20.2% (better) | −214% |
| Net margin | 23.9% (better) | −195% |
| FCF margin | −86.5% | – |
| Return on equity | 47.5% (better) | −43.3% |
| Return on invested capital | – | −161% |
| Financial health | ||
| Debt / equity | 0.00 | 0.05 (better) |
| Net debt / EBITDA | −3.53 | – |
| Current ratio | 4.10 | 8.03 (better) |
| Altman Z-score | −1.43 | 3.87 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 85.8% | 80.5% |
| Held by insiders | 9.6% | 2.1% |
| Insider net buying, 12 months | −$1.0M (better) | −$5.3M |
| Short interest, % of float | 8.3% | 15.4% |
Go deeper
- ALEC stock overview
- ALEC income statement
- ALEC valuation and score
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.